GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q3 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $180 million versus the consensus estimate of $188.52 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q4 2023 revenue of $188-194 million, versus the consensus of $192.7 million.

GoodRx Holdings, Inc. sees FY2023 revenue of $742-748 million, versus the consensus of $754.9 million.

For earnings history and earnings-related data on GoodRx Holdings, Inc. (GDRX) click here.